Nuclear Medicine Market Growth Supported by PET and SPECT Technologies
Author : Rutuja Deshmukh | Published On : 13 Nov 2026
The global Nuclear Medicine Market size was valued at USD 21.3 billion in 2025 and is projected to grow from USD 24.1 billion in 2026 to USD 38.2 billion by 2033, registering a CAGR of 6.8% from 2026 to 2033. North America dominated the market with a revenue share of 42.8% in 2025, while Asia Pacific is anticipated to record the fastest growth during the forecast period. Increasing demand for precision diagnostics, targeted cancer therapies, advanced imaging technologies, and radiopharmaceutical innovation is supporting market expansion. A robust product pipeline and favorable government initiatives to improve access to nuclear medicine are further strengthening industry growth.
Nuclear Medicine Market Overview
Nuclear medicine uses radioactive materials, known as radiopharmaceuticals, to diagnose and treat various diseases. It plays an important role in oncology, cardiology, neurology, and urology by enabling physicians to assess organ function, identify diseases, and deliver targeted treatments. Technologies such as Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT) are central to diagnostic applications.
The growing incidence of cancer and chronic diseases is increasing the need for accurate diagnostic procedures and specialized treatment options. Nuclear medicine also supports targeted radiation delivery, allowing physicians to direct treatment toward specific cancer cells while limiting exposure to surrounding healthy tissues.
The market is further benefiting from developments in theranostics, which combines diagnostic imaging and targeted radionuclide therapy. This approach supports patient selection, disease monitoring, and personalized treatment planning within a connected clinical pathway.
Key Market Trends and Insights
- Diagnostic products dominate: The diagnostic segment accounted for 76.8% of market revenue in 2025 and is expected to register the fastest CAGR during the forecast period.
- Urology leads applications: The urology segment held the largest application share of 23.6% in 2025, supported by demand for prostate cancer diagnosis and treatment.
- Hospitals remain the primary end users: The hospitals segment accounted for 57.0% of market revenue in 2025.
- North America leads regional demand: The region held a 42.8% revenue share in 2025.
- Asia Pacific records the fastest growth: Increasing healthcare investment and awareness of nuclear medicine therapies are supporting regional expansion.
- Theranostics gains importance: The integration of diagnostic imaging and targeted radionuclide treatment is strengthening the role of nuclear medicine in precision oncology.
Market Dynamics
Rising Adoption of Theranostics in Oncology
The increasing adoption of theranostics is a major driver of the nuclear medicine market. By combining diagnostic imaging with targeted radionuclide therapy, theranostics enables healthcare providers to identify suitable patients, evaluate disease progression, and deliver personalized treatment. The growing incidence of cancer and increasing emphasis on precision medicine are encouraging the use of these solutions across healthcare facilities.
Technological advancements and expanding radiopharmaceutical development are further supporting adoption. In December 2023, Lantheus Holdings, Inc. and POINT Biopharma Global Inc. announced topline results from the Phase 3 SPLASH study, which evaluated 177Lu-PNT2002 in patients with metastatic castration-resistant prostate cancer who had progressed following androgen receptor pathway inhibitor treatment. In 2025, Novartis also announced plans to expand its radioligand therapy manufacturing network to strengthen production capabilities and global supply.
Want to Understand What’s Driving Market Growth? Ask Prism AI for research-backed insights into market size, evolving opportunities
Limited Availability of Medical Isotopes and Supply Chain Constraints
The availability of medical isotopes remains a significant market restraint. Nuclear medicine procedures depend on a consistent supply of radioactive materials, while production, transportation, and distribution involve specialized infrastructure and logistical requirements. Supply chain limitations and shortages of skilled medical personnel can also affect access to nuclear medicine services.
Expansion of Alpha-Emitting Radiopharmaceutical Development
The development of alpha-emitting radiopharmaceuticals presents an important market opportunity. Therapeutic applications are supported by the development and commercialization of new radioisotopes. Radium-223 is currently identified as a widely used alpha emitter, while potential isotopes such as Terbium-149, Bismuth-212, and Actinium-225 are being developed to support future therapeutic applications.
Product Segment Analysis
The diagnostic segment dominated the nuclear medicine market with a 76.8% revenue share in 2025. Its growth is supported by the large patient population and increasing availability of advanced imaging technologies, including PET and SPECT. Radiotracers used to identify tumors and other diseases are contributing to the segment's expansion. According to the World Nuclear Association Analysis 2024, approximately 50 million nuclear medicine procedures are performed annually, while demand for radioisotopes increases by around 5% each year.
The therapeutic segment includes alpha emitters, beta emitters, and brachytherapy. Its growth is supported by a robust product pipeline and the approval of nuclear medicine-based treatments. In October 2021, the U.S. FDA approved and granted breakthrough designation to diffusing alpha-emitters Radiation Therapy for treating patients with recurrent glioblastoma multiforme.
Download a free sample report or claim your copy of this full market intelligence report
Application and End-Use Analysis
The urology segment accounted for the largest application revenue share of 23.6% in 2025 and is anticipated to grow at the fastest CAGR during the forecast period. Increasing cases of prostate cancer and demand for advanced diagnostic and treatment products are supporting this position. According to the World Cancer Research Fund International, approximately 1,467,854 new prostate cancer cases were reported worldwide in 2022.
The endocrine tumors segment is also expected to grow at a significant CAGR. Collaborations focused on diagnostic agents for PET imaging of somatostatin receptor-positive neuroendocrine tumors are supporting the development of this application area.
By end use, hospitals held the largest revenue share of 57.0% in 2025. Most therapeutic nuclear medicine procedures are conducted in hospital settings. The adoption of therapeutic radioisotopes such as Pluvicto and Lutathera, alongside additional products in development, is expected to support hospital demand.
Regional Market Insights
North America dominated the nuclear medicine market in 2025, accounting for 42.8% of global revenue. The region benefits from the adoption of advanced imaging technologies and innovative therapeutic radiopharmaceuticals. The rising prevalence of cancer and chronic conditions is further increasing demand. The U.S. held the largest share within North America, supported by widespread PET and SPECT adoption and the growing need for precise diagnostic procedures. However, supply chain limitations, logistical challenges, and shortages of skilled personnel remain concerns.
Europe's market growth is supported by expanding healthcare infrastructure and increasing demand for advanced diagnostic imaging and targeted treatment, particularly in oncology and cardiology. Germany dominated the European market in 2024, while the UK is benefiting from advancements in PET and SPECT imaging. Supportive healthcare policies and investments in medical infrastructure are also contributing to market development in France.
Asia Pacific is anticipated to register the fastest growth during the forecast period. Increasing awareness of nuclear medicine therapies, rising investments, and expanding healthcare services are supporting regional adoption. The development of specialized facilities and growing demand for nuclear imaging in China and Japan are further contributing to market expansion.
Latin America represents a lucrative market, with advancements in PET and SPECT technologies supporting diagnostic and treatment capabilities. Brazil dominated the regional market, although geographic challenges and socioeconomic disparities continue to affect access to services. In the Middle East and Africa, government investments in research and development are supporting product improvements and market development. Saudi Arabia is expected to experience growth as nuclear medicine applications expand across oncology, cardiology, neurology, and endocrinology.
Future Outlook
The nuclear medicine market is expected to benefit from increasing adoption of precision diagnostics, theranostics, and targeted radiopharmaceutical therapies. Advancements in PET and SPECT imaging, the development of new therapeutic isotopes, and investment in manufacturing infrastructure are creating opportunities across clinical applications. However, limited isotope availability, supply chain constraints, regulatory requirements, and high radiopharmaceutical costs may influence market development. Continued innovation and efforts to improve access to nuclear medicine services are expected to support long-term growth.
Explore Our Research & Intelligence Solutions
U.S. Healthcare Facility Intelligence: Make Better Decisions with Comprehensive Data – Explore the Platform
